Zoetis Inc.
ZTSHealthcareNASDAQDrug Manufacturers - Specialty & Generic
Scan Results
Daily timeframeZoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions. Valued at $31.33B, ZTS is a large-cap name in its sector. The company commercializes products primarily across companion animals comprising dogs, cats, and horses; and species, including livestock, such as cattle, swine, poultry, fish, and sheep.
Market Cap
$31.33B
Beta
0.73
P/E (TTM)
12.37
P/E (Fwd)
11.61
EPS (TTM)
$6.13
EPS (Fwd)
$6.53
ROE
64.9%
ROA
15.3%
Cash
$1.68B
Total Debt
$9.26B
Free CF
$2.02B
52W Change
-49.4%
Annual Financials
Cash vs Debt
Where ZTS stands vs its 150-day and 200-day moving averages
As of the August 24, 2026 close, ZTS finished 21.12% below its 150-day moving average ($98.54) and 25.36% below its 200-day moving average ($104.14). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ZTS overbought or oversold?
At the August 24, 2026 close, ZTS's RSI(14) was 51.1, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Zoetis Inc. carries $9.26B in total debt against $1.68B in cash reserves — debt is roughly 5.5x the cash position. Managing this leverage effectively will be important for long-term financial stability. The company generates $2.02B in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of 64.9% points to exceptionally high capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Return on assets of 15.3% further supports the picture of efficient asset utilization. Revenue has been uneven over recent years, ranging from $8.08B to $9.47B.
Zoetis Inc. carries a heavier debt load relative to its cash position, which introduces financial risk that investors should weigh. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing ZTS.